MREO compared with TXMD: revenue, margins and what each company keeps, and the suppliers and customers both name

MREOMereo BioPharma Group plc

Mkt capRevenueRevenue

TXMDTherapeuticsMD, Inc.

Mkt capRevenueRevenue

Compare

MREOMereo BioPharma Group plc

TXMDTherapeuticsMD, Inc.

Price

Mkt cap

Revenue

Revenue flow Supply chain Price Co-movers Event sensitivity Earnings history

Save comparison

Revenue flow

News Findings Companies A–Z Pricing Methodology Sources Corrections About Terms

Not investment advice. Not a broker-dealer. Indices shown as ETF proxies. Supply-chain data CC BY 4.0; market data not redistributable.

Listed on One’s Vibe · live-checked · Oct ’26

Desk News Calendar Saved

Revenue flow Supply chain Price Co-movers Event sensitivity Earnings history

Price

Supply-chain overlap

Revenue flow

MREO: latest quarter is a loss; flow not drawable. TXMD: latest quarter not drawable.Method ›

MREOMereo BioPharma Group plc

0.28▼−6.07%

Mkt cap$48.4MRevenue$500,000Q2 FY25Revenue—

TXMDTherapeuticsMD, Inc.

1.80▼−1.10%

Regular sessionNov 5 '26

Mkt cap$21.2MRevenue$869,000Q2 FY26Revenue$3MFY25

Compare

Regular sessionNov 5 '26

MREOMereo BioPharma Group plc

TXMDTherapeuticsMD, Inc.

0.28▼−6.07%

Price

1.80▼−1.10%

$48.4M

Mkt cap

$21.2M

Q2 FY25$500,000

Revenue

$869,000Q2 FY26

—

Revenue

$3MFY25

MREO0.28▼−6.07%vsTXMD1.80▼−1.10%Regular sessionNov 5 '26

Supply-chain overlap

direct ties · both sidesSources ›

direct ties · both sides

Only MREO 4

RAREUltragenyx Pharmaceuticalcustomer

AZNAstraZeneca ABsupplier

—Feng Biosciencesunlistedcustomer

—ReproNovounlistedcustomer

Shared 0

No disclosed counterparties: TXMD.

Only TXMD 0

None

Role chip = supplier or customer—= no ticker (unlisted)Source: SEC EDGAR

Price

rebased to 0%

MREO, solidTXMD, dashed